Home › Funds › Ensign Peak Advisors, Inc › BSX
Ensign Peak Advisors, Inc position in BSX
BOSTON SCIENTIFIC CORP · Health Care
Ensign Peak Advisors, Inc reported holding 5,881,367 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q2 2026 13F filing — a position valued at US$251.0M, representing 0.41% of its reported portfolio and ranking #44 among its reported holdings. Ensign Peak Advisors, Inc has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ensign Peak Advisors, Inc's BSX position evolved
Ensign Peak Advisors, Inc first disclosed a stake in BSX in Q3 2023 at 1,858,961 shares (US$98.2M). The position peaked in Q1 2026 at 4,507,242 shares, worth US$282.8M. Across 12 filings, Ensign Peak Advisors, Inc increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 5,881,367 shares valued at US$251.0M — an increase of 1,374,125 shares quarter over quarter.. Notable position changes include a 37% trim in Q1 2025 (shares rose 6% over the following quarter), a 186% increase in Q1 2026 (shares fell 32% over the following quarter), a 30% increase in Q2 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.86M | $98.15M | New |
| Q4 2023 | 1.93M | $111.79M | Add |
| Q1 2024 | 2.23M | $152.58M | Add |
| Q2 2024 | 1.85M | $142.27M | Reduce |
| Q3 2024 | 1.68M | $141.04M | Reduce |
| Q4 2024 | 1.54M | $137.19M | Reduce |
| Q1 2025 | 974.16K | $98.27M | Reduce |
| Q2 2025 | 1.25M | $134.42M | Add |
| Q3 2025 | 1.48M | $144.05M | Add |
| Q4 2025 | 1.58M | $150.44M | Add |
| Q1 2026 | 4.51M | $282.83M | Add |
| Q2 2026 | 5.88M | $251.02M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include Banque Cantonale Vaudoise (US$2.89B), PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- Banque Cantonale Vaudoise 67.61K sh · $2.89B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 50.52M sh · $2.16B · Q2 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
- Arrowstreet Capital 23.29M sh · $994.18M · Q2 2026
- Bollard Group LLC 18.42M sh · $786.20M · Q2 2026
More on Ensign Peak Advisors, Inc
FAQ
How long has Ensign Peak Advisors, Inc held BSX?
Ensign Peak Advisors, Inc has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Ensign Peak Advisors, Inc's current position in BSX?
As of Q2 2026, Ensign Peak Advisors, Inc holds 5.88M shares of BSX (BOSTON SCIENTIFIC CORP), valued at $251.02M, representing 0.41% of its reported portfolio and ranking #44.
Has Ensign Peak Advisors, Inc been buying or selling BSX?
In the latest 13F filing (Q2 2026), Ensign Peak Advisors, Inc increased its position in BSX. The position peaked in Q1 2026 at 4.51M shares.
Which other funds hold BSX?
Other major institutional holders of BSX include Banque Cantonale Vaudoise, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.